Investment platform
Русский
Беларускі
Español
Nektar
Sell70.22
Spread1.37
Buy71.59

Trade Nektar Therapeutics - NKTR stock price

Sell70.22
Spread1.37
Buy71.59
1m
5m
15m
30m
1H
4H
1D
1W
History
Open on platform
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.
White Paper Declaration

Trade the world’s top tokenised stocks, indices, commodities and currencies with the help of crypto or fiat

Download on the App Store Get it on Google Play None Explore platform Show QR
Articles
Hedera price risks 20% drop as TVL and dApp revenue decline
Read more
Bitcoin on-chain loss metrics hit 2022 Luna collapse levels at higher prices
Read more
Aztec perpetuals: Binance rolls out 5x futures on privacy L2 asset
Read more
Coinbase stock at risk ahead of earnings as Robinhood’s crypto revenue dip
Read more
1 BTC
Invest
50 BTC
Profit
Leverage:
x50

The Power Of Leverage

Trade in the big leagues with 100 Bitcoin for every 1 Bitcoin you put in

NKTR price history

  • Last 7 days
  • Last 30 days
  • Last Year
  • Last 2 Years
  • Maximum Period
  • Daily
  • Weekly
  • Monthly
Date Close Change Chg% Open Min. Max.
2022-09-30 65.57 6.82 11.61 58.75 58.12 67.5
2022-09-30 55.34 8.50 18.15 46.84 46.81 56.34
2022-09-30 36.67 1.28 3.62 35.39 35.21 37.38
2022-09-30 36.41 1.76 5.08 34.65 34.31 36.99
2022-09-30 34.79 -1.97 -5.36 36.76 34.7 38.23
2022-09-30 37.26 -0.70 -1.84 37.96 35.81 38.07
2022-09-30 38.6 0.75 1.98 37.85 37.14 38.79
2022-09-30 37.92 1.08 2.93 36.84 36.66 39.19
2022-09-30 36.98 2.26 6.51 34.72 33.23 37.44
2022-09-30 34.85 -0.37 -1.05 35.22 34.67 36.02
2022-09-30 35.59 -1.89 -5.04 37.48 35.55 38.0
2022-09-30 37.75 3.33 9.67 34.42 34.42 38.14
2022-09-30 36.85 0.65 1.80 36.2 35.6 37.28
Go help.dzengi.com
Dzengi.com Exchange
Trade BTC & tokenized stocks